前收市價 | 14.49 |
開市 | 14.60 |
買盤 | 16.04 x 300 |
賣出價 | 16.12 x 100 |
今日波幅 | 14.60 - 17.04 |
52 週波幅 | 3.94 - 17.42 |
成交量 | |
平均成交量 | 451,883 |
市值 | 806.446M |
Beta 值 (5 年,每月) | 1.58 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -3.74 |
業績公佈日 | 2024年5月09日 - 2024年5月13日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 20.15 |
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.
Thursday, ALX Oncology Holdings (NASDAQ:ALXO) reported a fourth-quarter 2023 EPS loss of $(0.93), missing the consensus of $(0.86). As of December 31, 2023, cash equivalents and investments were $218.1 million. The company says the cash balance and the ability to draw down an additional $40 million of its term loan are sufficient to fund planned operations into early 2026. In October 2023, ALX Oncology released prespecified interim Phase 2 data from its ASPEN-06 trial of evorpacept plus trastuzu